Evaluation of single nucleotide variants in DNA repair and cell cycle control genes in multiple myeloma patients undergoing hematopoietic stem cell transplant and their association with clinical outcomes
Funding Cycle:
2023-2024Name:
David GarridoType of Award:
Career Development AwardHome Institution:
Hospital de Clínicas Dr. Manuel Quintela, Montevideo, UruguayHost Institution:
The Experimental Medicine and Biology Institute, Buenos Aires, ArgentinaDescription
Autologous Stem Cell Transplantation represents a widely accessible therapy in Latin America, particularly crucial given the limited availability of new medications in the region, including monoclonal antibodies, next-generation proteasome inhibitors, immunomodulators, and advanced cellular therapies.
This study aims to assess the impact of the genetic profile, particularly single nucleotide variants (SNVs), on the clinical outcomes of multiple myeloma (MM) patients following consolidation with high-dose melphalan (HDM) and ASCT. Initially, we identified SNVs through PCR amplification and Sanger sequencing of relevant genetic regions. Subsequently, a comprehensive pharmacogenomic analysis was conducted using the Illumina Infinium Global Screening Array v3.0 (GSA). Key outcomes include response rate, progression-free survival, and overall survival.
